The FRACTURE Trial is a prospective, non-randomized, single-arm, multicenter, interventional study in US and international centers.
The FRACTURE Trial is a prospective, non-randomized, single-arm, multicenter, interventional study in US and international centers with the Bolt Intravascular Lithotripsy System that was designed to percutaneous transluminal angioplasty by utilizing delivery of IVL to disrupt calcium prior to full balloon dilatation at low pressures.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
420
Lithotripsy-enhanced percutaneous coronary intervention of de novo, calcified, stenotic coronary artery lesions prior to stenting.
Primary Safety Endpoint
Freedom from major adverse cardiac events (MACE) within 30 days following the index procedure.
Time frame: Within 30 days following procedure
Primary Effectiveness Endpoint
Procedural success defined as successful stent delivery with a final residual stenosis \<50% (assessed by angiographic core laboratory) and freedom from in-hospital MACE.
Time frame: Immediately after the intervention/procedure/surgery
Device success
The ability to deliver the Bolt IVL catheter across the target lesion, and delivery of lithotripsy without serious angiographic complications immediately after IVL.
Time frame: Immediately after the intervention/procedure/surgery
Angiographic success (at <50%)
Stent delivery with \<50% final residual stenosis and without serious angiographic complications.
Time frame: Immediately after the intervention/procedure/surgery
Procedural success
Stent delivery with a final residual stenosis ≤30% and without in-hospital MACE.
Time frame: Immediately after the intervention/procedure/surgery
Angiographic success (at ≤30%)
Stent delivery with ≤30% final residual stenosis and without serious angiographic complications.
Time frame: Immediately after the intervention/procedure/surgery
Serious angiographic complications
Severe dissection (Type D to F), perforation, abrupt closure, and persistent slow flow or persistent no reflow.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Scripps Health
La Jolla, California, United States
Cedars-Sinai Heart Institute
Los Angeles, California, United States
Riverside Community Hospital
Riverside, California, United States
Southern California Permanente Medical Gp. / Kaiser Permanente
San Diego, California, United States
Los Robles Hospital & Medical Center
Thousand Oaks, California, United States
Medical Center of the Rockies
Loveland, Colorado, United States
Nova Clinical Research Centers/Manatee Memorial Hospital
Bradenton, Florida, United States
The Cardiac & Vascular Institute
Gainesville, Florida, United States
HCA FL Memorial Hospital
Jacksonville, Florida, United States
HCA Florida Largo Hospital
Largo, Florida, United States
...and 36 more locations
Time frame: Immediately after the intervention/procedure/surgery
MACE
MACE within 6, 12, and 24 months.
Time frame: within 6, 12, and 24 months.
Target lesion failure (TLF)
Cardiac death, target vessel myocardial infarction (TV-MI) (Q wave and non-Q wave), or ischemia-driven target lesion revascularization (ID-TLR) by percutaneous or surgical methods at 30 days, 6 months, 12 months, and 24 months.
Time frame: 30 days, 6 months, 12 months, and 24 months
All deaths, cardiac deaths, MIs, TV-MIs, procedural and nonprocedural MIs, ID-TVRs, ID-TLRs, non-ID-TLRs, non-ID-TVRs, all revascularizations (ID and non-ID), and stent thrombosis
All deaths, cardiac deaths, MIs, TV-MIs, procedural and nonprocedural MIs, ID-TVRs, ID-TLRs, non-ID-TLRs, non-ID-TVRs, all revascularizations (ID and non-ID), and stent thrombosis (Academic Research Consortium (ARC) definite, probable, definite or probable).
Time frame: Periprocedure, within 30 days, 6 months, 12 months, and 24 months